PatSnap Synapse
2023-06-0941 Pages

Global Drug R&D Express (May 2023)

report cover
Abstract
Based on the latest data from PatSnap Synapse, Zhihuiya has released the "Global Drug R&D Express (May 2023)". The report includes a total of 75 drugs consisting of: ◉ 18 drugs first approved globally: 5 Small molecule drug (SMD), 4 Monoclonal antibody(mAb), 2 Prophylactic vaccine, 2 Allergen extract, 1 Blood components, 1 Gene therapy, 1 Bispecific antibody, 1 Enzyme, 1 Fusion protein. ◉ 57 drugs under Expedited Review pathways worldwide: 32 Orphan Drug designation, 12 Fast Track designation, 5 Priority review, 4 Breakthrough Therapy designation, 2 Regenerative Medicine Advanced Therapy, 1 Innovative Licensing and Access Pathway (ILAP), 1 Accelerated Approval. The report also highlights: ◼ 5 first approved drugs: Benegrastim, Fezolinetant, Zebituzumab, Perfluorohexyloctane, Beremagene geperpavec ◼ 5 Expedited Review Pathway drugs: Spesolimab, Mefatinib, Resiniferatoxin, Nirsevimab, Fruquintinib, providing a detailed interpretation of the drugs from multiple aspects such as basic information, R&D status, technical barriers, mechanisms of action, clinical trials, and competitive landscape.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free